Recent developments include AIM ImmunoTech’s final approval of a novel cancer therapy patent in Japan, multiple announcements regarding rights offerings to raise capital, and analyst coverage maintaining buy recommendations.

• AIM ImmunoTech received final approval of a novel cancer therapy patent in Japan, supporting its intellectual property portfolio [N1].
• The company announced changes to key dates and terms related to a rights offering in January 2026 to raise capital [N3][N4].
• Analyst Ascendiant Capital maintained a buy recommendation on AIM ImmunoTech in December 2025 [N5].
• AIM’s stock performance and positioning relative to medical peers were discussed in January 2026 articles [N2].

AIM ImmunoTech's development of Ampligen for late-stage pancreatic cancer addresses a significant unmet medical need with a large global patient population. The company’s ongoing Phase 2 DURIPANC study combining Ampligen with AstraZeneca’s durvalumab could provide clinical data supporting further development and potential partnerships or acquisitions. The granted patents and orphan drug designations in major markets enhance exclusivity and commercial potential. Recent capital raises and patent approvals, including in Japan, support continued clinical and regulatory activities. Experienced leadership with biotech, legal, and financial expertise supports strategic execution.

AIM ImmunoTech faces financial challenges including negative stockholders' equity and a working capital deficit, leading to NYSE American compliance warnings. The company’s revenues are minimal relative to operating losses, and it depends on capital raises to fund operations. Manufacturing relies on limited suppliers without long-term agreements, posing supply chain risks. Clinical development is subject to regulatory and scientific uncertainties, and Ampligen is not yet approved by the FDA. The biotech sector’s competitive landscape and regulatory environment add execution risks. Failure to maintain listing compliance or secure sufficient funding could materially impact operations.

AIM ImmunoTech's moat is based on its proprietary nucleic acid-based therapeutic Ampligen, which has established clinical and preclinical data supporting its use in pancreatic cancer and other indications. The company holds patents and orphan drug designations in key markets including the US, Japan, and Europe, providing market exclusivity and intellectual property protection. Its focus on a large unmet medical need in pancreatic cancer, combined with ongoing clinical trials in combination therapies, positions it within a niche segment of oncology therapeutics. However, the company operates in a highly competitive and regulated biotech environment with significant development and commercialization risks, and limited manufacturing supply agreements.

• Financial and Liquidity Risks: The company has a working capital deficit and negative stockholders' equity, raising substantial doubt about its ability to continue as a going concern without successful capital raises and cost management.
• Regulatory and Clinical Development Risks: Ampligen is not FDA approved in the US, and clinical trials may not demonstrate sufficient safety or efficacy to support regulatory approval or commercialization.
• Manufacturing and Supply Chain Risks: AIM relies on a limited number of suppliers and contract manufacturers without long-term supply agreements, which could cause production delays or increased costs.
• Market and Competitive Risks: The oncology and biotech markets are highly competitive with rapid innovation, and AIM faces competition from other therapies and companies.
• Listing Compliance Risks: The company’s stockholders' equity is below NYSE American minimum requirements, and failure to regain compliance could lead to delisting, affecting liquidity and capital access.

• AIM ImmunoTech Inc. is an immuno-pharma company headquartered in Ocala, Florida, focused on developing Ampligen for late-stage pancreatic cancer treatment.
• The company’s flagship product is Ampligen (rintatolimod), a double-stranded RNA molecule developed for cancers, viral diseases, and immune system disorders.
• Ampligen is approved for commercial sale in Argentina for severe Chronic Fatigue Syndrome but not approved by the FDA in the US.
• AIM is conducting clinical trials evaluating Ampligen’s efficacy and safety in pancreatic cancer and exploring its use in combination with checkpoint inhibitors and as a vaccine adjuvant.
• The company also markets Alferon N Injection (Interferon alfa).
• AIM completed a rights offering in March 2026 raising approximately $1.8 million in gross proceeds.
• The company has a sales agreement with Maxim Group LLC to issue and sell up to $3 million of common stock via an ATM offering.
• As of December 31, 2025, AIM had cash and cash equivalents of approximately $2.985 million and current liabilities of $6.224 million, resulting in a current ratio of 0.53 and a cash ratio of 0.67.
• For the fiscal year ended December 31, 2025, AIM reported revenues of $88,000 and a net loss of $13.958 million, with basic and diluted EPS of -$8.62.
• The company’s stockholders’ equity was negative $9.783 million as of December 31, 2025, below the NYSE American minimum equity requirement of $6 million, leading to a compliance warning.
• AIM’s management has plans to regain compliance with NYSE American listing requirements by June 2026, including capital raises and reclassification of warrant liabilities.
• The company’s board includes experienced executives with backgrounds in biotech, law, finance, and leadership, including CEO Thomas K. Equels and Chair William M. Mitchell, M.D., Ph.D.
• AIM’s research and development expenses for 2025 were approximately $3.9 million, including clinical studies and manufacturing costs.
• The company relies on a limited number of suppliers for raw materials and manufacturing of Ampligen and Alferon N Injection, with contracts in place with Jubilant HollisterStier LLC and Pharmaceutics International Inc. for manufacturing and fill & finish services.
• AIM’s DURIPANC Phase 2 study is evaluating Ampligen combined with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor durvalumab in metastatic pancreatic cancer patients.
• The company recognizes revenue primarily from clinical treatment programs in the US under cost recovery protocols.
• AIM has received orphan drug designations and holds patents for Ampligen in the US, Japan, and Europe, supporting market exclusivity in pancreatic cancer.
• The company’s net cash used in operating activities was approximately $10.957 million for the year ended December 31, 2025.
• AIM’s recent news includes final approval of a novel cancer therapy patent in Japan and announcements related to rights offerings and capital raises.
• The company’s stock price was approximately $0.70 as of March 28, 2026.